ReAlta Life Sciences has announced the closing of an oversubscribed $40 million financing, bringing the total capital raised to date to more than $150 million. The company will use the proceeds to advance pegtarazimod through key clinical and regulatory milestones as the first potential treatment for Hypoxic Ischemic Encephalopathy (HIE). Upcoming milestones for this first-in-class […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!